Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9706)
All Articles published online
|
Publishing Process of This Article
|
Sep 28, 2015 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Salvado M, Vargas V, Vidal M, Simon-Talero M, Camacho J, Gamez J. Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. World J Gastroenterol 2015; 21(36): 10475-10479 [PMID: PMC4579895 DOI: 10.3748/wjg.v21.i36.10475] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v21/i36/10475.htm |
| Number | Citing Articles |
| 1 |
Sebastiano Giuseppe Crisafulli, Simona Brajkovic, Maria Sara Cipolat Mis, Valeria Parente, Stefania Corti. Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis. Molecular Neurobiology 2018; 55(4): 2789 doi: 10.1007/s12035-017-0532-4
|
| 2 |
Jesus S. Mora, Angela Genge, Adriano Chio, Conrado J. Estol, Delia Chaverri, Maria Hernández, Saúl Marín, Javier Mascias, Gabriel E. Rodriguez, Monica Povedano, Andrés Paipa, Raul Dominguez, Josep Gamez, Maria Salvado, Christian Lunetta, Carlos Ballario, Nilo Riva, Jessica Mandrioli, Alain Moussy, Jean-Pierre Kinet, Christian Auclair, Patrice Dubreuil, Vincent Arnold, Colin D. Mansfield, Olivier Hermine. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020; 21(1-2): 5 doi: 10.1080/21678421.2019.1632346
|
| 3 |
Arsh Haj Mohamad Ebrahim Ketabforoush, Rojin Chegini, Shirin Barati, Fatemeh Tahmasebi, Bardia Moghisseh, Mohammad Taghi Joghataei, Faezeh Faghihi, Fereshteh Azedi. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomedicine & Pharmacotherapy 2023; 160: 114378 doi: 10.1016/j.biopha.2023.114378
|
| 4 |
Natalia Papadopoulos, Johan Lennartsson. The PDGF/PDGFR pathway as a drug target. Molecular Aspects of Medicine 2018; 62: 75 doi: 10.1016/j.mam.2017.11.007
|
| 5 |
Bethany D. Latham, D. Spencer Oskin, Rachel D. Crouch, Matthew J. Vergne, Klarissa D. Jackson. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chemical Research in Toxicology 2022; 35(9): 1467 doi: 10.1021/acs.chemrestox.2c00057
|
| 6 |
Franz Felix Konen, Nora Möhn, Torsten Witte, Matthias Schefzyk, Miriam Wiestler, Svjetlana Lovric, Karsten Hufendiek, Konstantin Fritz Jendretzky, Stefan Gingele, Philipp Schwenkenbecher, Kurt-Wolfram Sühs, Manuel A. Friese, Luisa Klotz, Refik Pul, Marc Pawlitzki, David Hagin, Christoph Kleinschnitz, Sven G. Meuth, Thomas Skripuletz. Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders. Autoimmunity Reviews 2025; 24(4): 103754 doi: 10.1016/j.autrev.2025.103754
|
| 7 |
A. O. Bueverov, E. L. Bueverova. Medically-induced autoimmune hepatitis: a rare disease or a rare diagnosis?. Dokazatel'naya gastroenterologiya 2017; 6(1): 47 doi: 10.17116/dokgastro20176147-55
|
| 8 |
Mehdi Brahmi, Philippe A. Cassier. Masitinib for gastrointestinal stromal tumors. Expert Opinion on Orphan Drugs 2016; 4(6): 671 doi: 10.1080/21678707.2016.1180973
|
| 9 |
H Blasco, F Patin, CR Andres, P Corcia, PH Gordon. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy 2016; 17(12): 1669 doi: 10.1080/14656566.2016.1202919
|
| 10 |
|
| 11 |
Abdullah Ashraf Hamad, Basma Ehab Amer, Yousef Hawas, Manar Alaa Mabrouk, Mostafa Meshref. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence. Neurological Sciences 2024; 45(5): 1861 doi: 10.1007/s10072-023-07259-w
|
| 12 |
Sebastian A. Lewandowski, Linda Fredriksson, Daniel A. Lawrence, Ulf Eriksson. Pharmacological targeting of the PDGF-CC signaling pathway for blood–brain barrier restoration in neurological disorders. Pharmacology & Therapeutics 2016; 167: 108 doi: 10.1016/j.pharmthera.2016.07.016
|
| 13 |
David E. Kleiner. Recent Advances in the Histopathology of Drug-Induced Liver Injury. Surgical Pathology Clinics 2018; 11(2): 297 doi: 10.1016/j.path.2018.02.009
|